Information Technology · Services-Prepackaged Software

DH Definitive Healthcare Corp. SEC Filings & Insider Trading Activity 2026

company
CIK 186179571 filings
Russell 2000

DH at a glance

Definitive Healthcare Corp. (DH, SEC CIK 1861795) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Definitive Healthcare Corp. (DH) reported revenue of $241.5 million (down 4.2% from FY2024) and a net loss of $138.9 million. Diluted EPS was -$1.30.
  • As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Definitive Healthcare Corp. (DH) shares worth $8.8 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$241.5M
−4.2% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
22 funds
$8.8M · −2 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • Regulatory/legal risk: Sales tax liabilities from prior misclassification of products and services, now addressed by voluntary disclosures and registrations to avoid future penalties
  • Macroeconomic/geopolitical risk: Customer churn, particularly in Life Sciences market, driven by macroeconomic headwinds and international trade/tariff uncertainties impacting spending
  • Operational/supply chain risk: Disruptions in healthcare claims data market since early 2024 leading to renegotiations and potential higher acquisition costs for key data sources
  • Competitive/market disruption risk: Sales execution challenges from 2024 restructuring impacting new customer acquisition and upsell, risking market position against established SaaS competitors
  • Financial risk: Significant goodwill impairments over last three years totaling $1.17 billion due to sustained market capitalization declines and stock price drops

AI summary of the DH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $54.7M, down 9% YoY from $60.0M, driven by $5.5M lower subscription revenue
  • Gross margin 77.3% vs 76.6% YoY, with gross profit $42.2M vs $46.0M
  • Existing-customer revenue fell $8.4M, partially offset by $3.0M from new customers
  • Cash $177.1M plus $12.8M short-term investments, with $34.4M operating cash flow through nine months
  • 2026 outlook: negative revenue growth, pressured by churn, elongated deal cycles, and sales execution challenges

Risk Factors

  • Nasdaq delisting risk: bid price fell below $1.00 for 30 consecutive business days, though compliance was regained October 30, 2026
  • Acquisition proposal risk: Advent submitted a non-binding indication of interest on September 2, 2026
  • Strategic transaction risk: proposal uncertainty could divert management time and resources
  • Legal risk: litigation connected to the Advent proposal could generate substantial costs
  • Financing risk: potential Nasdaq delisting could limit access to debt and equity financing

AI summary of the DH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Definitive Healthcare’s detailed results and management commentary are in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $54.7M, down 9% YoY, signaling continued top-line pressure despite customer wins and expansion activity
  • Net loss narrowed to $5.4M from $17.8M, while adjusted EBITDA fell to $15.7M from $18.9M
Filed Sep 9, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • TRA holders waived Early Termination Payments for qualifying change-of-control deals with definitive agreements executed by December 31, 2026
  • Waiver reduces potential acquisition-related cash obligations, potentially improving transaction economics for buyers
Filed Sep 2, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Clay Ritchey appointed CEO and director effective September 8, 2026, replacing Kevin Coop
  • Healthcare technology executive with prior CEO experience at Verato, Evariant, and Equinox Healthcare

Item EX-99.1: Item EX-99.1

  • Clay Ritchey appointed CEO and director effective September 8, 2026
  • Kevin Coop departed both roles effective August 31, 2026 after serving as CEO since June 2024

AI summaries of DH 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for DH

Don't miss the next DH filing

  • Alerts as it files. A push when DH files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut DH, by share count.
  • Ask anything. An AI agent that reads every DH filing and answers with sources.

DH alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Krantz Jason RonaldFNov 1, 2026$1.12
Heller CaseyFNov 1, 2026$1.12
Ritchey Clay BrianAOct 23, 2026-
Paris JonathanFOct 1, 2026$0.94
Heller CaseyFOct 1, 2026$0.94
Heller CaseyFSep 1, 2026$0.90
Heller CaseyFAug 1, 2026$0.68
Krantz Jason RonaldFAug 1, 2026$0.68

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$251.4M$252.2M$241.5M
Gross Profit-$197.5M$183.3M
Operating Income--$710.8M-$224.3M
Net Income--$413.1M-$138.9M
Gross Margin-78.3%75.9%
Op. Margin--281.8%-92.9%
Net Margin--163.8%-57.5%
Balance Sheet
Total Assets-$1.1B$735.5M
Equity-$607.2M$379.0M
ROE--68.0%-36.7%
Per Share
EPS-$-3.54$-1.30
Cash Flow
Operating CF-$58.2M$53.8M
CapEx$3.0M$12.3M$16.7M

Source: XBRL data in Definitive Healthcare Corp. (DH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate DH share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
DH shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202622$8.8M
Q2 202624$13.4M
Q1 202626$24.2M
Q4 202525$58.6M
Q3 202524$93.4M
Q2 202525$97.3M
Q1 202521$61.6M
Q4 202419$50.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 186 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

DH filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
4Nov 3, 2026--
4Nov 3, 2026--
4Oct 27, 2026--
4Oct 5, 2026--
4Oct 5, 2026--
8-KSep 9, 2026Analysis-
4Sep 3, 2026--
8-KSep 2, 2026Analysis-
SC 13DSep 2, 2026-
8-KSep 2, 2026Analysis-
SC 13DSep 2, 2026-
8-KAug 10, 2026Analysis-
10-QAug 10, 2026Analysis
4Aug 4, 2026--
4Aug 4, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
8-KJun 24, 2026Analysis-
4Jun 9, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
8-KJun 5, 2026Analysis

Related Information Technology companies

All Information Technology →

DH SEC filings: frequently asked questions

Which institutions hold DH stock?

As of September 30, 2026, the largest Definitive Healthcare Corp. (DH) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($1.7 million), D.E. Shaw & Co ($1.3 million), Dimensional Fund Advisors ($1.3 million), Goldman Sachs Group ($977,000), Renaissance Technologies LLC ($882,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was DH's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Definitive Healthcare Corp. (DH) reported revenue of $241.5 million (down 4.2% from FY2024) and a net loss of $138.9 million. Diluted EPS was -$1.30. The figures come from the XBRL data in the 10-K.

What are the main risks in DH's latest 10-K?

In the 10-K filed February 26, 2026, Definitive Healthcare Corp. (DH) flagged: Regulatory/legal risk: Sales tax liabilities from prior misclassification of products and services, now addressed by voluntary disclosures and registrations to avoid future penalties. Macroeconomic/geopolitical risk: Customer churn, particularly in Life Sciences market, driven by macroeconomic headwinds and international trade/tariff uncertainties impacting spending. (AI summary of the Risk Factors section.)

What did DH report in its latest 8-K?

Definitive Healthcare Corp. (DH) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest DH SEC filings?

Definitive Healthcare Corp. (DH) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 3, 2026.

What is DH's SEC CIK number?

Definitive Healthcare Corp. (DH)'s SEC Central Index Key (CIK) is 1861795. EDGAR lists every DH filing under that number.

Ask anything about DH

The research agent reads DH's filings, financials, insider trades and 13F holders, then answers with sources.